Sec Form 3 Filing - NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG @ HORIZON PHARMA, INC. - 2011-07-28

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG 2. Issuer Name and Ticker or Trading Symbol HORIZON PHARMA, INC. [ HZNP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O HORIZON PHARMA, INC., 1033 SKOKIE BLVD., SUITE 355 3. Date of Earliest Transaction (MM/DD/YY) 07/28/2011 (Street) NORTHBROOK, IL60062 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 51,731 D ( 1 ) Common Stock 71,556 D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series A Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 401,927 D ( 1 ) Series A Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 555,956 D ( 2 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 44,364 D ( 1 ) Series B Preferred Stock ( 3 ) ( 3 ) ( 3 ) Common Stock 61,366 D ( 2 ) Convertible Promissory Notes ( 4 ) ( 4 ) ( 4 ) Common Stock 805,856.5 ( 4 ) D ( 1 ) Convertible Promissory Notes ( 4 ) ( 4 ) ( 4 ) Common Stock 114,665.38 ( 4 ) D ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG C/O HORIZON PHARMA, INC. 1033 SKOKIE BLVD., SUITE 355 NORTHBROOK, IL60062 X NGN BioMed Opportunity I L P C/O HORIZON PHARMA, INC. 1033 SKOKIE BLVE., SUITE 355 NORTHBROOK, IL60062 X Signatures /s/ See Exhibit 99.1 07/28/2011 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Securities held in the name of NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG. ( 2 )Securities held in the name of NGN Biomed Opportunity I, L.P. ( 3 )The shares of Series A Preferred Stock and Series B Preferred Stock have no expiration date and are convertible at any time at the election of the holder. Every 2.374 shares of preferred stock will automatically convert into one share of common stock upon the closing of the Issuer's initial public offering. ( 4 )Principal and accrued interest will convert upon the Issuer's initial public offering into shares of Common Stock at a conversion price equal to the lesser of (i) the public offering price of the Common Stock sold in the Issuer's initial public offering, or (ii) $18.92. Amounts shown are reported in US dollars and include interest accrued through the date hereof; additional interest will accrue prior to conversion.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.